Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00389168
Status:
COMPLETED
Last Update Posted:
2015-05-05
First Post:
2006-10-17
Brief Title:
Irbesartan and Atenolol in Hypertensive Heart Disease
Sponsor:
Karolinska Institutet
Organization:
Karolinska Institutet
Study Overview
Official Title:
Randomized Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SILVHIA
Brief Summary:
The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature beyond the effects on blood pressure
This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and vascular structure and function in subjects with hypertensionPatients with hypertension and left ventricular hypertrophy were randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48 weeks Repeat investigations of blood pressure structure and function of the heart and the vascular tree and neurohormones were performed Two control groups consisting of normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also examined for comparison
This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and vascular structure and function in subjects with hypertensionPatients with hypertension and left ventricular hypertrophy were randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48 weeks Repeat investigations of blood pressure structure and function of the heart and the vascular tree and neurohormones were performed Two control groups consisting of normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also examined for comparison
Detailed Description:
We included 115 patients with hypertension and cardiac hypertrophy established by echocardiography Extensive echocardiographic examinations ultrasonography of the carotid arteries 24h Holter registrations 24h ambulatory blood pressure monitoring monitoring neurohormones and blood samples for inflammation and hemostasis markers and endothelial function were done at weeks 0 12 24 and 48 Matched control groups 13 ie 38 normotensive subjects and 38 hypertensive subjects with no signs of hypertensive heart disease were examined at one occasion All patients obtained irbesartan or atenolol for 12 weeks a diuretic and a calcium antagonist was added when needed thereafter in order to obtained a blood pressure below 14090 mm Hg All analyses were performed central in a core laboratory
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None